We herein provide an overview of the clinical laboratory tests that should be performed before, during and after using therapeutic monoclonal antibodies (mAbs) and the clinical laboratory tests that may be affected by mAbs.
| BACKGROUND
Monoclonal antibodies (mAb) are antibodies that are made by identical immune cells derived from a unique parent B lymphocyte cell. 1 During the past few decades, mAbs have become an integral and widely used technology for both laboratory diagnostics and clinical treatment. 2, 3 As it the case for many other prescription drugs, it is necessary to perform clinical laboratory tests before and after the treatment with therapeutic mAb to screen for potentially sensitive patients, check the patients' background health status and to evaluate the response to treatment.
It has also been reported that some mAbs may interfere with clinical laboratory tests, especially diagnostic kits that use mAb to detect a specific analyte. 4, 5 However, to the best of our knowledge, there have not been any systematic review about the clinical laboratory tests needed for and affected by therapeutic mAb based on the drug labels.
Drug labels provide an excellent source of data for pharmacoepidemiological studies because they contain detailed information about the individual drugs. Therefore, we reviewed and analyzed all the labels of FDA-approved therapeutic mAbs deposited in DailyMed, the official website for FDA-approved drug labels (https://dailymed.
nlm.nih.gov/dailymed/index.cfm), to provide a detailed profile of the clinical laboratory tests which should be performed before, during and/or after the treatment with therapeutic mAbs, and information about the mAbs that have the potential to affect clinical laboratory tests.
| COLLECTION OF DATA OF FDA-APPROVED MABS
We downloaded PDF labels for all therapeutic mAbs from the DailyMed database (https://dailymed.nlm.nih.gov/dailymed/), which contains nearly all of the labels for US FDA-approved drugs. If there were duplicate labels for the same therapeutic mAb from different manufacturers, or the labels were updated at different times, only the latest label was used for the study. A hyperlink was established to access the information conveniently, and the findings for each Mab are presented in Table 1 .
Stemmed keywords were used to search the label contents for relevant information. These keywords included "analy*", "assay", "clinic*", "determine*", "lab*" and "test" to cover the potentially useful information to the best extent possible. Every stemmed keyword represented several words potentially related to clinical laboratory testing (eg, "analy" was used to find information related to "analyse(d)(s)", "analyze(d)(s)", "analysis", "analyte", and "analytical"). The first two authors of the manuscript, respectively, searched the documents and input the data. When there were differences in the descriptions found between the authors, they discussed the findings with the other authors, and the group's consensus regarding the findings was used for the analysis.
| OVERVIEW OF THE FDA-APPROVED MABS
More than 100 therapeutic mAbs have been approved by FDA so far.
But there were only 50 therapeutic mAb available on the US market as of May 2016, because the others (i.e., gemtuzumab 20 and efalizumab
21
) had been withdrawn due to a lack of efficacy, adverse reactions, or loss of market share (replaced by other treatments).
The currently marketed therapeutic mAbs are generally used to treat cancer, autoimmune disease (e.g., rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and systemic lupus erythematosus), microbial infections, and rejection. The treatment of cancer is the field with the most therapeutic mAbs, and is also the main direction of development. In total, 20 therapeutic mAbs (>40% of the currently marketed therapeutic mAbs) are being used for the treatment of cancer.
| CLINICAL LABORATORY TESTS FOR MABS
The most practical finding of this study was that most of the labels for human therapeutic mAbs provide explicit information related to clinical laboratory testing. Most of the information was about the clinical laboratory tests that need to be performed before treatment and the influence of mAb treatment on the accuracy of clinical laboratory tests.
| Clinical laboratory tests needed before mAb treatment
Some patients taking therapeutic mAbs may develop side effects, mainly immunotoxicity. One of the aim of performing clinical laboratory tests before mAbs treatment is to avoid this situation. Most of the therapeutic mAbs used to treat autoimmune diseases and rejection target immune system-related molecules located on the surface cell membranes. 22 For example, TNF-α is the target of adalimumab, certolizumab-PEG and infliximab. The targets for basiliximab, canakinumab and ixekizumab are IL-2Rα, IL-1β, and IL-17A, respectively ( For some therapeutic mAbs, especially those used for cancer treatment, screening for potentially sensitive patients is needed to determine whether the drug is expected to have an effect. Trastuzumab, which inhibits HER2-mediated signals that promote tumor growth, is used to treat the patients with HER2-positive breast and gastric cancer. Cancer patients should be screened using FDA-approved diagnostic kits before the treatment to confirm that they express HER2. Such selection limits the treatment to those who should respond to the drug. Therefore, determining whether a mAbs would be effective for a patient is another aim of performing clinical laboratory tests before mAbs treatment.
According to the reasons mentioned above, clinical laboratory tests are need before treatment of more than half of FDA-approved mAb drugs. Accurately, there are 32 mAbs need to perform clinical laboratory tests before their treatment (Table 1) .
| Clinical laboratory tests needed during/after mAb treatment
Laboratory tests monitoring for safety and efficacy in patients is needed for all drugs, and mAbs are no exception. The mAbs are usually better tolerated than small molecules because they are more specific for the target and do not interact with cytochrome P450 or other transport proteins in the body, resulting in a reduced potential for drug/drug interactions. However, while they are generally well tolerated, mAbs may be associated with adverse events (AEs) such as hepatotoxicity, nephrotoxicity, and hematotoxicity. Many AEs are target-related, and will be specific to the antibody target and the therapeutic area of use.
Alternatively, mAbs may cause toxicity by interacting with the target antigen on tissues other than the intended tissue. For example, skin toxicity is associated with cetuximab (used to treat colorectal and head and neck cancer), which inhibits the epidermal growth factor receptor
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Muromonab-Cd3 (EGFR) ( Table 1 ). The skin toxicity is thought to be due to the expression of the target antigen, EGFR, on human keratinocytes. Usually, tests for electrolyte and dermatologic toxicities are need for patients receiving cetuximab treatment (Table 1) . Non-specific toxicity may also occur during treatment with mAbs; for example, hypersensitivity reactions are commonly observed that are thought to be related to the immunogenicity of mAbs. 25 The immunogenicity is ability of a particular substance to induce an immune response in human body. In 1986, muromonab-CD3 (trade name Orthoclone OKT3) was approved by the US Food and Drug Administration (FDA) as the first therapeutic mAb (Table 1) , which was used to reduce acute rejection in organ transplant patients. 26 However, these early products were murine antibodies, which led to allergic reactions and reduced the efficacy of the drugs. Following progress made in recombinant DNA technology, the technology developed from the use of murine mAb to chimeric mAb to humanized mAb and ultimately to fully human mAb. (Table 1) .
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Early diagnosis and close clinical monitoring are essential for the successful management of adverse events during treatment with mAbs. It is crucial for clinicians to test the corresponding indicators of these reactions in real time. In the event of a severe side effect, dose adaptation, a change in treatment, or complete cessation of treatment should be implemented if necessary. Table 1 presents the reported side effects of the various therapeutic mAbs. Therefore, clinical laboratory tests are needed during/after treatment of most of current FDA-approved mAb drugs (Table 1 ).
| Clinical laboratory tests influenced by mAb treatment
Since the 1970s when mAb technology was developed, mAbs have become common and essential research and clinical diagnostic tools for many applications, including enzyme-linked immunosorbent assays (ELISAs), Western blotting, immunohistochemistry, immunoprecipitation, and cytometric analysis. The use of mAbs is important for the identification of proteins, carbohydrates, and nucleic acids. Compared to polyclonal antibodies, the mAbs have been proved to be more sensitive and specific. Because mAbs are widely used for both clinical diagnostics and disease treatment, there may be cross-reactions for some laboratory tests. For example, palivizumab, a therapeutic mAb against respiratory syncytial virus (RSV) F glycoprotein, has been observed to interfere with immunologically based RSV diagnostic assays in laboratory studies. 27 As required, the label for the drug points out that it is not possible to test for RSV infection using an immunoassay during treatment with palivizumab, and reverse transcriptase-polymerase chain reaction (RT-PCR) should be used instead. In other cases, the interference is unexpected. For example, abatacept, which targets CTLA4, interferes with blood glucose testing ( 
| PERSPECTIVES: WHEN, WHY, AND WHAT IS EXPECTED FOR LABORATORY TESTS?
Since the commercialization of the first therapeutic mAb product in 1986, this class of agents has been used in a variety of clinical treatments, including those for cancer, allograft rejection, autoimmune disorders, infectious diseases, and inflammatory disorders. As biotechnology and bioinformatics continue to advance, new targets for therapeutic mAb will be found and studied. 22, 28, 29 In fact, there is already a higher approval rate for mAbs than other biopharmaceutical products, and the global sales of monoclonal antibody products have grown faster than those of other products in recent years. 30 The last decade has witnessed a more extensive and widespread use of therapeutic mAb in clinical treatment. Based on the current approval rate of new products per year, there should be 70 therapeutic mAb products on the market by 2020, and combined worldwide sales will be nearly $125 billion. 30 Thus, there is a need to continue investigations into the testing that should be performed before, during, and after treatment with mAbs, and extensive surveillance to determine what laboratory tests may be affected by treatment with these agents.
The therapeutic mAbs exhibit high specificity for their targets. The efficacy of a mAb depends on the characteristics of the targeted antigen, including its function, the cell-surface density and tissue distribution, as well as the characteristics of the mAb, including its specificity, avidity, and isotype. These factors are also associated with the risk of adverse effects for these mAbs.
Therapeutic mAbs can induce unexpected interference with laboratory tests via several mechanisms, including direct crossreactions with the test reagents, the suppression of physiological functions in the patient, activation of inflammatory processes after binding of the mAb to its target. 31 Detecting or knowing about the interference and using an alternative method to run the laboratory test are critical to ensure the accuracy of results and safety of patients. 20 It is critical to eliminate the influence of interference on clinical practice. The most practical strategy for managing the concerns about laboratory interference is to enhance the communication between the laboratory staff and clinicians. When laboratory reports show non-conformity with the status or medication history of the patient, the possibility of interference should be considered and investigated. In addition, the incorporation of such information into automated laboratory software would help to alert staff members to potential interference.
| CONCLUSION
Drug labels are legal documents that contain all of the important information about a given drug, and provide legal guidance regarding the use of the medication. Hence, it is important for the manufacturer to provide all related information as precisely and in the greatest detail possible. As such, the US FDA has promulgated a series of standards to explicitly guide the production of drug labels.
32,33
Although the DailyMed database provides a convenient source of drug labels, clinicians and laboratory personnel may not have the time to search for and keep abreast of the laboratory tests affected by mAbs. Therefore, we herein provided this report which offers comprehensive and convenient information regarding the clinical laboratory tests associated with various mAbs. The information includes both the testing that should be performed before, during, or after treatment, and the potential interference that may be encountered. We believe that our brief report and the included table can serve as a handy reference for clinical laboratory staff and clinicians to provide better diagnostic services and treatment.
In conclusion, we have herein provided a comprehensive summary of the interference reported for the current FDA-approved therapeutic mAbs, as well as a list of the tests that must be performed before, during or after treatment to ensure the best patient outcome. 
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